Item 8.01. Other Events
On October 15, 2013, Synthetic Biologics, Inc. (the "Company") issued the
attached press release that included information related to the successful
completion of the protein expression evaluation by FUJIFILM Diosynth
Biotechnologies UK Limited (Fujifilm) with regard to the Company's proprietary
oral beta-lactamase enzyme (SYN-004) targeting the prevention of Clostridium
difficile (C. difficile or C. diff) infections and the manufacturing of SYN-004
material to support Synthetic Biologics' planned preclinical and clinical
studies pursuant to an agreement with Fujifilm entered into on October 8, 2013.
A copy of the press release is attached as Exhibit 99.1 to this Report on Form
8-K. The information contained in the press release is being furnished to the
Commission and shall not be deemed incorporated by reference into any of the
Registrant's registration statements or other filings with the Commission.
Item 9.01. Financial Statements and Exhibits
The following exhibit is being filed as part of this Report.
99.1 Press release issued by Synthetic Biologics, Inc. dated October 15, 2013.
- 2 -